You are currently viewing a new version of our website. To view the old version click .

New Insight to Overcome Tumor Resistance: Molecular and Cellular Mechanism

This special issue belongs to the section “Cell Biology and Tissue Engineering“.

Special Issue Information

Dear Colleagues,

This Special Issue focuses on translational science in the hopes of shedding light on overcoming novel tumour therapy resistance. In fact, acquired drug resistance is one of the main restrictions to the efficacious treatment of cancer. There are many data showing that resistance results from drug exclusion, drug metabolism, and modification of the drug target by mutation or overexpression. Depending on the therapy, one or more genetic or epigenetic modulations are required to confer resistance to treatment.

The editor already works in a translational team from bench to bedside. She welcome submissions from researchers involved in basic cancer research but also in clinical activities. She has a deep knowledge of cancer therapy and target therapy such as tyrosine kinase and cyclin-kinases inhibitor, examined with the most different methods, biochemistry, immunohistochemistry, immunofluorescence, RT-qPCR, NGS, etc. It is required to have a clear understanding of tumour cells, and to clarify the ways that lead to therapy resistance from cell lines to clinical trials. Reviews and original papers are both welcome.

Dr. Nicoletta Cordani
Dr. Emanuela Grassilli 
Dr. Geeta Sharma
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer therapy resistance
  • target therapy
  • liquid biopsy
  • circulating cancer DNA
  • exosomes in cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Published Papers

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Life - ISSN 2075-1729